© 2002 by European Society of Cardiology
Copyright © 2002, European Society of Cardiology
Pharmacological possibilities for protection against myocardial reperfusion injury
aDepartment of Integrative Pharmacology, AstraZeneca R&D, Mölndal, Sweden
bDepartment of Cardiology, Karolinska Hospital, Box 60500, S-171 76 Stockholm, Sweden
* Corresponding author. Tel.: +46-8-5177-5876; fax: +46-8-311-044 john.pernow{at}ks.se
Reperfusion through thrombolysis or percutananeous coronary angioplasty is standard treatment in impending acute myocardial infarction. Although restoration of blood flow to the jeopardised myocardial area is a perquisite for myocardial salvage, reperfusion itself may lead to accelerated and additional myocardial injury beyond that generated by ischemia alone. This is referred to as the "reperfusion injury". Since the reperfusion injury is initiated by the treatment of myocardial infarction, it is of importance to limit the extent of the injury. Several studies aimed at preventing reperfusion injury by means of pharmacological agents have therefore been conducted. The design of such studies is crucial for the results. Factors of importance are the timing of drug administration, animal species used, the degree of collateral flow and the duration of ischemia. A variety of pharmacological compounds have been investigated in different experimental models of myocardial ischemia and reperfusion. These include oxygen free radical scavengers, antioxidants, calcium channel blockers, inhibitors of neutrophils, nitric oxide, adenosine-related agents, inhibitors of the renin-angiotensin system, endothelin receptor antagonists, Na+/H+ exchange inhibitors, and anti-apoptotic agents. All these groups of pharmacological agents have been demonstrated to protect from reperfusion injury determined as limitation of infarct size, improved myocardial and endothelial function, and reduced incidence of arrhythmias. The mechanism behind the protective effect may differ between different groups of compounds, but some compounds may exert cardioprotection via common pathways. Such a pathway may be via maintained bioavailability of nitric oxide.
KEYWORDS Reperfusion; Free radicals; Nitric oxide; Endothelins; Na/H-exchanger; Angiotensin; Leukocytes
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M.A. H. Talukder, J. L. Zweier, and M. Periasamy Targeting calcium transport in ischaemic heart disease Cardiovasc Res, December 1, 2009; 84(3): 345 - 352. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.M. Binda and P.R. Koninckx Prevention of adhesion formation in a laparoscopic mouse model should combine local treatment with peritoneal cavity conditioning Hum. Reprod., June 1, 2009; 24(6): 1473 - 1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Dirksen, G. J. Laarman, M. L. Simoons, and D. J.G.M. Duncker Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies Cardiovasc Res, June 1, 2007; 74(3): 343 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lanoye, P. Segers, V. Tchana-Sato, S. Rolin, J.-M. Dogne, A. Ghuysen, B. Lambermont, J. Hanson, T. Desaive, P. Verdonck, et al. Cardiovascular Control: Cardiovascular haemodynamics and ventriculo-arterial coupling in an acute pig model of coronary ischaemia-reperfusion Exp Physiol, January 1, 2007; 92(1): 127 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Z. Zhu, C. L. Chong, S. C. Chuah, S. H. Huang, H. S. Nai, H. T. Tong, M. Whiteman, and P. K. Moore Cardioprotective effects of nitroparacetamol and paracetamol in acute phase of myocardial infarction in experimental rats Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H517 - H524. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Darling, R. Jiang, M. Maynard, P. Whittaker, J. Vinten-Johansen, and K. Przyklenk Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2 Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1618 - H1626. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. F. Thompson, H. K. Eltzschig, J. C. Ibla, C. J. Van De Wiele, R. Resta, J. C. Morote-Garcia, and S. P. Colgan Crucial Role for Ecto-5'-Nucleotidase (CD73) in Vascular Leakage during Hypoxia J. Exp. Med., December 6, 2004; 200(11): 1395 - 1405. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. F. Merrill, T. H. Rork, N. M. Spiler, and R. Golfetti Acetaminophen and myocardial infarction in dogs Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1913 - H1920. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hobbs, P. Foster, C. Prescott, R. Scotland, and A. Ahluwalia Natriuretic Peptide Receptor-C Regulates Coronary Blood Flow and Prevents Myocardial Ischemia/Reperfusion Injury: Novel Cardioprotective Role for Endothelium-Derived C-Type Natriuretic Peptide Circulation, September 7, 2004; 110(10): 1231 - 1235. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A Bogoyevitch An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection Cardiovasc Res, August 1, 2004; 63(2): 208 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Liem, C. C. Gho, B. C. Gho, S. Kazim, O. C. Manintveld, P. D. Verdouw, and D. J. Duncker The Tyrosine Phosphatase Inhibitor Bis(Maltolato)Oxovanadium Attenuates Myocardial Reperfusion Injury by Opening ATP-Sensitive Potassium Channels J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1256 - 1262. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E Mangoni and S. Barrere-Lemaire Adenosine receptors, heart rate, and cardioprotection Cardiovasc Res, June 1, 2004; 62(3): 447 - 449. [Full Text] [PDF] |
||||
![]() |
M. T Dirksen, G. Laarman, A. W.J van 't Hof, G. Guagliumi, W. A.L Tonino, L. Tavazzi, D. J.G.M Duncker, M. L Simoons, and on behalf of the PARI-MI Investigators The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty: Safety and efficacy of a novel tetrapeptide, ITF-1697 Eur. Heart J., March 1, 2004; 25(5): 392 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Eefting, B. Rensing, J. Wigman, W. J. Pannekoek, W. M. Liu, M. J. Cramer, D. J Lips, and P. A Doevendans Role of apoptosis in reperfusion injury Cardiovasc Res, February 15, 2004; 61(3): 414 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Yarbrough, R. Mukherjee, G. P. Escobar, J. W. Hendrick, J. A. Sample, K. B. Dowdy, J. E. McLean, J. T. Mingoia, F. A. Crawford Jr, and F. G. Spinale Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion Ann. Thorac. Surg., December 1, 2003; 76(6): 2054 - 2061. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pernow, F. Bohm, E. Beltran, and A. Gonon L-Arginine protects from ischemia-reperfusion-induced endothelial dysfunction in humans in vivo J Appl Physiol, December 1, 2003; 95(6): 2218 - 2222. [Abstract] [Full Text] |
||||
![]() |
W. M. Yarbrough, R. Mukherjee, G. P. Escobar, J. T. Mingoia, J. A. Sample, J. W. Hendrick, K. B. Dowdy, J. E. McLean, R. E. Stroud, and F. G. Spinale Direct inhibition of the sodium/hydrogen exchanger after prolonged regional ischemia improves contractility on reperfusion independent of myocardial viability J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1489 - 1497. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Mentzer Jr, R. D. Lasley, A. Jessel, and M. Karmazyn Intracellular sodium hydrogen exchange inhibition and clinical myocardial protection Ann. Thorac. Surg., February 1, 2003; 75(2): S700 - 708. [Abstract] [Full Text] [PDF] |
||||










